Skip to content

Cognitive and Motor Benefits of Standing

Kognitivne in Gibalne Prednosti stoječega Delovnega Mesta (KOGIS)

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03944564
Acronym
KOGIS
Enrollment
20
Registered
2019-05-09
Start date
2019-09-10
Completion date
2022-09-01
Last updated
2021-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Acute, Muscle Tone Abnormalities, Work-Related Condition, Sensory Deficit

Keywords

cognition, brain activity, cognitive reserve, work productivity, musculoskeletal discomfort, attention

Brief summary

Upright-working has been proven to benefit health by combating the negative effects of physical inactivity. However, long-term commitment to static standing regimens may be limited due to symptoms of musculoskeletal fatigue that may develop during prolonged static standing in the absence of facilitated weight shifting. We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification.

Detailed description

Within-group design to study the effects of standing-and-working accompanied by periodic movement compared to standing-and-working and to sitting-and-working on measures of musculoskeletal fatigue and discomfort, and physiological measures, in healthy normal control subjects, middle-aged to older adults. Measures of musculoskeletal and subjective discomfort and fatigue will be assessed in three sessions, i.e. seated, static standing, and dynamic standing (see below). During these test sessions subjects will perform small assignments using a computer mimicking light office work, including several tests measuring attention span. The first session will be the seated condition for all participants. Sessions 2 and 3 will be randomized between static or dynamic standing. Prior to any research procedures, written informed consent will be obtained from each subject followed by initial study eligibility screening. Eligibility screening includes clinical screening questions, including, but not limited to, questions regarding significant history of cardiovascular disease, history of lower extremity pain and fractures, back pain, and migraines. Subjects will stand behind a height adjustable table that is positioned about 0.5 meters from a wall. For the static standing position subjects will be asked to stand behind the table. No specific restrictions for standing will be imposed on subjects (e.g. do not move or stand quietly). For the dynamic standing condition participants will stand behind the same table but received periodic cues to induce weight-shifting steps. A seated control session condition will also be used to get baseline musculoskeletal subjective ratings for the same time period. Each sitting or standing session will not exceed 4 hour. As many rest breaks will be provided to the subject as needed. The entire test session may take up to approximately 5 hours. The experimental testing protocol will be conducted preferably in the morning over three or more different days. Each day will be dedicated to one testing condition. Subjects will stand on an anti-fatigue mat during the static and dynamic standing sessions. For the standing conditions, rest breaks (e.g. sitting or walking around) will be provided as needed. During the study session caffeine consumption will be prohibited in order to standardize the stimulant effect of caffeine across subjects.

Interventions

BEHAVIORALSitting

We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)

BEHAVIORALStatic standing

We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)

We propose a dynamic standing approach (working while standing accompanied by small periodic stepping movements) as a more tolerable and thereby more applicative lifestyle modification. To evaluate this form on healthy subjects, three different conditions will be applied: 4 hours of sitting, static standing and dynamic standing. Both standing conditions will be done with height-adjustable table which was developed at the University of Michigan (Ann Arbor, Michigan, USA)

Sponsors

University of Michigan
CollaboratorOTHER
Science and Research Centre Koper
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Masking description

Participants will receive a general information about the study protocol and received three conditions in a random order.

Intervention model description

Randomized, controlled crossover trial

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

1\. Healthy adults (both gender, age range 18-64 years) who are currently employed.

Exclusion criteria

1. Inability to stand or walk without an assistive device 2. History of symptoms in stance that preclude safe and comfortable participation, such as dizziness and lightheadedness, orthostasis, severe symptomatic leg or back musculoskeletal pain, or medication side effects 3. History of symptomatic cardiovascular or pulmonary disease 4. History of rheumatic arthritis 5. History of stroke or other neurologic conditions with residual sensorimotor deficits 6. History of chronic pain syndrome requiring narcotic analgesics 7. Neurological disorders 8. Evidence of dementia 9. Diabetics: low or poorly controlled blood glucose 10. Any other history of medical or psychiatric comorbidity precluding safe participation in the project

Design outcomes

Primary

MeasureTime frameDescription
Overall movement - accelerometrychange in activity levels between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)Overall movement (counts/min)
Musculoskeletal discomfortchange in musculoskeletal discomfort levels between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)Rate of total musculoskeletal discomfort development (mm/min)
Leg swellingchange in leg swelling levels between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)Average swelling for both legs (cm)

Secondary

MeasureTime frameDescription
Oxygen uptakechange in oxygen consumption between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)Oxygen uptake VO2 (ml/min/kg)
Brain electrocortical activitychange in electrocortical activity levels between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)EEG measurements (frequency analysis and ERP analysis)
Attention levelschange in attentional levels between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)Measuring attention with Stroop test (seconds)
Executive controlchange in executive control and cognitive switching levels between all three conditions, which will be measured on average 3 days in-between (maximum length of measurements per subject = 15 days)Executive functions measured with TMT test (seconds)

Countries

Slovenia

Contacts

Primary ContactUros Marusic, PhD
uros.marusic@zrs-kp.si041529226

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026